The evolutionary mechanism of cancer
- PMID: 20213744
- DOI: 10.1002/jcb.22497
The evolutionary mechanism of cancer
Abstract
Identification of the general molecular mechanism of cancer is the Holy Grail of cancer research. Since cancer is believed to be caused by a sequential accumulation of cancer gene mutations, the identification, characterization, and targeting of common genetic alterations and their defined pathways have dominated the field for decades. Despite the impressive data accumulated from studies of gene mutations, epigenetic dysregulation, and pathway alterations, an overwhelming amount of diverse molecular information has offered limited understanding of the general mechanisms of cancer. To solve this paradox, the newly established genome theory is introduced here describing how somatic cells evolve within individual patients. The evolutionary mechanism of cancer is characterized using only three key components of somatic cell evolution that include increased system dynamics induced by stress, elevated genetic and epigenetic heterogeneity, and genome alteration mediated natural selection. Cancer progression represents a macro-evolutionary process where karyotype change or genome replacement plays the key dominant role. Furthermore, the recently identified relationship between the evolutionary mechanism and a large number of diverse individual molecular mechanisms is discussed. The total sum of all the individual molecular mechanisms is equal to the evolutionary mechanism of cancer. Individual molecular mechanisms including all the molecular mechanisms described to date are stochastically selected and unpredictable and are therefore clinically impractical. Recognizing the fundamental importance of the underlying basis of the evolutionary mechanism of cancer mandates the development of new strategies in cancer research.
Similar articles
-
Evolutionary mechanisms and diversity in cancer.Adv Cancer Res. 2011;112:217-53. doi: 10.1016/B978-0-12-387688-1.00008-9. Adv Cancer Res. 2011. PMID: 21925306 Review.
-
Cancer progression by non-clonal chromosome aberrations.J Cell Biochem. 2006 Aug 15;98(6):1424-35. doi: 10.1002/jcb.20964. J Cell Biochem. 2006. PMID: 16676347 Review.
-
Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective.J Cell Physiol. 2009 Sep;220(3):538-47. doi: 10.1002/jcp.21799. J Cell Physiol. 2009. PMID: 19441078 Review.
-
The dynamics of cancer chromosomes and genomes.Cytogenet Genome Res. 2007;118(2-4):237-46. doi: 10.1159/000108306. Cytogenet Genome Res. 2007. PMID: 18000376 Review.
-
Stochastic cancer progression driven by non-clonal chromosome aberrations.J Cell Physiol. 2006 Aug;208(2):461-72. doi: 10.1002/jcp.20685. J Cell Physiol. 2006. PMID: 16688757
Cited by
-
Temozolomide promotes genomic and phenotypic changes in glioblastoma cells.Cancer Cell Int. 2016 May 5;16:36. doi: 10.1186/s12935-016-0311-8. eCollection 2016. Cancer Cell Int. 2016. PMID: 27158244 Free PMC article.
-
Family Malvaceae: a potential source of secondary metabolites with chemopreventive and anticancer activities supported with in silico pharmacokinetic and pharmacodynamic profiles.Front Pharmacol. 2024 Oct 16;15:1465055. doi: 10.3389/fphar.2024.1465055. eCollection 2024. Front Pharmacol. 2024. PMID: 39478959 Free PMC article.
-
Chromosomal heterogeneity and instability characterize pediatric medulloblastoma cell lines and affect neoplastic phenotype.Cytotechnology. 2013 Oct;65(5):871-85. doi: 10.1007/s10616-012-9529-z. Epub 2013 Jan 17. Cytotechnology. 2013. PMID: 23325114 Free PMC article.
-
Karyotypic determinants of chromosome instability in aneuploid budding yeast.PLoS Genet. 2012;8(5):e1002719. doi: 10.1371/journal.pgen.1002719. Epub 2012 May 17. PLoS Genet. 2012. PMID: 22615582 Free PMC article.
-
Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation.Mol Cytogenet. 2010 Oct 19;3:20. doi: 10.1186/1755-8166-3-20. Mol Cytogenet. 2010. PMID: 20959006 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources